Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:169069.
doi: 10.1155/2015/169069. Epub 2015 Mar 11.

Modulation of miRNAs in Pulmonary Hypertension

Affiliations
Review

Modulation of miRNAs in Pulmonary Hypertension

Sudhiranjan Gupta et al. Int J Hypertens. 2015.

Abstract

MicroRNAs (miRNAs) have emerged as a new class of posttranscriptional regulators of many cardiac and vascular diseases. They are a class of small, noncoding RNAs that contributes crucial roles typically through binding of the 3'-untranslated region of mRNA. A single miRNA may influence several signaling pathways associated with cardiac remodeling by targeting multiple genes. Pulmonary hypertension (PH) is a rare disorder characterized by progressive obliteration of pulmonary (micro) vasculature that results in elevated vascular resistance, leading to right ventricular hypertrophy (RVH) and RV failure. The pathology of PH involves vascular cell remodeling including pulmonary arterial endothelial cell (PAEC) dysfunction and pulmonary arterial smooth muscle cell (PASMC) proliferation. There is no cure for this disease. Thus, novel intervention pathways that govern PH induced RVH may result in new treatment modalities. Current therapies are limited to reverse the vascular remodeling. Recent studies have demonstrated the roles of various miRNAs in the pathogenesis of PH and pulmonary disorders. This review provides an overview of recent discoveries on the role of miRNAs in the pathogenesis of PH and discusses the potential for miRNAs as therapeutic targets and biomarkers of PH at clinical setting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
miRNA biogenesis. The miRNAs are transcribed by RNA polymerase II as primary transcript of miRNA (pri-miRNA). The pri-miRNA is the cleaved by RNase III enzyme, Drosha, along with several cofactors including DGCR8 and produces the stem-loop precursor miRNA (pre-miRNA). The pre-miRNA is then exported out of the nucleus by Exportin-5 to the cytoplasm. In the cytoplasm, the pre-miRNA is diced-up by Dicer resulting miRNA duplex, ~22 nucleotides long. The mature miRNA is incorporated into the RNA-induced silencing complex (RISC) which contains Argonaute (Ago) and is guided to the 3′-UTR of target mRNAs. The gene silencing is achieved by either mRNA degradation or translational repression.

References

    1. Humbert M., Montani D., Evgenov O. V., Simonneau G. Definition and classification of pulmonary hypertension. Handbook of Experimental Pharmacology. 2013;218:3–29. doi: 10.1007/978-3-642-38664-0-1. - DOI - PubMed
    1. Guignabert C., Dorfmuller P. Pathology and pathobiology of pulmonary hypertension. Seminars in Respiratory and Critical Care Medicine. 2013;34(5):551–559. doi: 10.1055/s-0033-1356496. - DOI - PubMed
    1. Tuder R. M., Stacher E., Robinson J., Kumar R., Graham B. B. Pathology of pulmonary hypertension. Clinics in Chest Medicine. 2013;34(4):639–650. doi: 10.1016/j.ccm.2013.08.009. - DOI - PubMed
    1. Maron B. A., Loscalzo J. Pulmonary hypertension: pathophysiology and signaling pathways. Handbook of Experimental Pharmacology. 2013;218:31–58. doi: 10.1007/978-3-642-38664-0_2. - DOI - PubMed
    1. New developments in pulmonary hypertension/pulmonary arterial hypertension. Proceedings of Pulmonary Hypertension UP2DATE 2008—post Dana Point. March 14-15, 2008. Munich, Germany. Deutsche Medizinische Wochenschrift. 2008;133(supplement 6):S165–S218. - PubMed